Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection[2].In Vitro: Pyronaridine tetraphosphate (24 h) shows anti-P. falciparum activity with an IC50 value of 1.53-3.94 nM.
In Vivo: Pyronaridine (57 mg/kg, oral administration, q.d. for 30 days) tetraphosphate reduces the parasitic burden in the Echinococcus granulosus-infected mice[2].
Pyronaridine (57 mg/kg, intraperitoneal injection, q.d. for 3 days) tetraphosphate reduces the parasitic burden in secondarily infected (cysts) mice[2].
Pyronaridine (57 mg/kg, intraperitoneal injection, for a single dose) tetraphosphate exhibits a higher exposure in the liver than in the plasma in male ICR mice[2].